Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Colorectal Neoplasms 64Head and Neck Neoplasms 63Squamous Cell Carcinoma of Head and Neck 60Carcinoma, Non-Small-Cell Lung 34Rectal Neoplasms 23Colonic Neoplasms 23Neoplasm Metastasis 19Neoplasms 18Carcinoma, Squamous Cell 17Pancreatic Neoplasms 13Lung Neoplasms 13Esophageal Neoplasms 11Tongue Neoplasms 9Stomach Neoplasms 9Recurrence 9Carcinoma 8Neoplasms, Squamous Cell 6Mouth Neoplasms 6Laryngeal Neoplasms 6Breast Neoplasms 6Adenocarcinoma Of Esophagus 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Esophageal Squamous Cell Carcinoma 5Adenocarcinoma of Lung 5Sarcoma 4Salivary Gland Neoplasms 4Oropharyngeal Neoplasms 4Laryngeal Diseases 4Precancerous Conditions 3Hypopharyngeal Neoplasms 3

Interventions

Mitoxantrone 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Androgen-independent Prostate Cancer × Cetuximab × Clear all
NCT00661492 2016-12-09

Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)

US Oncology Research

Phase 2 Completed
115 enrolled 16 charts
Genitourinary

Androgen-independent Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡